Ligand Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00626418
- Locations
- πΊπΈ
MD Clinical, Hallandale Beach, Florida, United States
πΊπΈSleep Disorders Center of Georgia, Atlanta, Georgia, United States
πΊπΈCommunity Research, Crestview Hills, Kentucky, United States
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00623324
- Locations
- πΊπΈ
Miami Research Associates, Miami, Florida, United States
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT00522925
- Locations
- πΊπΈ
Premiere Pharmaceutical Research, LLC, Tempe, Arizona, United States
πΊπΈClinical Trials Research, Lincoln, California, United States
πΊπΈLong Beach Center for Clinical Research, Long Beach, California, United States
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00458016
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00163137
- Locations
- πΊπΈ
Pfizer Investigational Site, Seattle, Washington, United States
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2011-08-10
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 497
- Registration Number
- NCT00143273
- Locations
Pfizer Investigational Site
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-08-15
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 8556
- Registration Number
- NCT00141323
- Locations
- π¬π§
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom
Bexarotene in Treating Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT00003752
- Locations
- πΊπΈ
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
πΊπΈArizona Cancer Center, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLymphoma
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Ligand Pharmaceuticals
- Registration Number
- NCT00006345
- Locations
- πΊπΈ
Veterans Affairs Medical Center - Miami, Miami, Florida, United States
πΊπΈRush Cancer Institute, Chicago, Illinois, United States
πΊπΈTulane University School of Medicine, New Orleans, Louisiana, United States
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00073736
- Locations
- πΊπΈ
University of California at Irvine, Orange, California, United States
ππ°Prince of Wales Hospital - Comprehensive Cancer Trial Unit, Shatin, New Territories, Hong Kong
π¨π³Tri-Services General Hospital, Taipei, Nei Hu District, Taiwan